Literature DB >> 15598947

Inhibitory effect of recombinant adenovirus carrying melittin gene on hepatocellular carcinoma.

C-Q Ling1, B Li, C Zhang, D-Z Zhu, X-Q Huang, W Gu, S-X Li.   

Abstract

OBJECTIVES: To search for a new clinical application of melittin (Mel): treating hepatocellular carcinoma with Mel gene.
METHODS: Recombinant adenoviruses carrying the Mel gene and alpha-fetoprotein (AFP) promoter (Ad-rAFP-Mel) were constructed through a bacterial homologous recombinant system. The efficiency of adenovirus-mediated gene transfer and the inhibitory effect of Ad-rAFP-Mel on the proliferation of hepatocarcinoma cells were determined by X-gal stain and MTT assay, respectively. The tumorigenicity of hepatocarcinoma cells transfected by Ad-rAFP-Mel and the antitumor effect of Ad-rAFP-Mel on transplanted tumor in nude mice were detected in vivo.
RESULTS: The Mel mRNA was transcribed in BEL-7402 hepatocellular carcinoma cells transducted by Ad-rAFP-Mel. The efficiency of adenovirus-mediated gene transferred to BEL-7402 cells was 100% when the multiplicity of infection of Ad-rAFP-Mel was 10 in vitro, and was also high in vivo. The inhibitive rates of Ad-rAFP-Mel and Ad-rAFP for BEL7402 cells were 66.2 +/- 2.7% and 2.9 +/- 2.3% (t=30.83, P=6.6 x 10(-6)) by MTT assay. The inhibitive rates of Ad-CMV-Mel for BEL7402, SMMC7721 and L02 cells were 58.9 +/- 9.6%, 65.9 +/- 3.8% and 31.7 +/- 1.2%, respectively, and of Ad-rAFP-Mel were 66.2 +/- 2.7%, 16.1 +/- 6.6% and 7.5 +/- 3.3%, respectively (t=1.27, P=0.27; t=11.31, P=3.5 x 10(-4); and t=12.12, P=2.7 x 10(-4) versus the Ad-CMV-Mel group in the same cells). The tumorigenicity rates of hepatocarcinoma cells transfected by Ad-rAFP-Mel were decreased. A significant antineoplastic effect was detected on transplanted tumor in nude mice by intratumoral injection of Ad-rAFP-Mel.
CONCLUSIONS: Ad-rAFP-Mel can inhibit specifically proliferation of AFP-producing human hepatocarcinoma cells in vitro and in vivo. This suggests that animal toxin gene can be used as an antitumor gene.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15598947     DOI: 10.1093/annonc/mdi019

Source DB:  PubMed          Journal:  Ann Oncol        ISSN: 0923-7534            Impact factor:   32.976


  9 in total

Review 1.  Studies on anticancer activities of antimicrobial peptides.

Authors:  David W Hoskin; Ayyalusamy Ramamoorthy
Journal:  Biochim Biophys Acta       Date:  2007-11-22

Review 2.  Melittin, a major peptide component of bee venom, and its conjugates in cancer therapy.

Authors:  Islam Rady; Imtiaz A Siddiqui; Mohamad Rady; Hasan Mukhtar
Journal:  Cancer Lett       Date:  2017-05-20       Impact factor: 8.679

3.  Claudin-6 and claudin-9 function as additional coreceptors for hepatitis C virus.

Authors:  Aihua Zheng; Fei Yuan; Yanqin Li; Fangfang Zhu; Pingping Hou; Jianqing Li; Xijun Song; Mingxiao Ding; Hongkui Deng
Journal:  J Virol       Date:  2007-09-05       Impact factor: 5.103

Review 4.  Experimental models of hepatocellular carcinoma: developments and evolution.

Authors:  Long Wu; Zhao-You Tang; Yan Li
Journal:  J Cancer Res Clin Oncol       Date:  2009-04-28       Impact factor: 4.553

5.  Development of optimized AAV3 serotype vectors: mechanism of high-efficiency transduction of human liver cancer cells.

Authors:  B Cheng; C Ling; Y Dai; Y Lu; L G Glushakova; S W Y Gee; K E McGoogan; G V Aslanidi; M Park; P W Stacpoole; D Siemann; C Liu; A Srivastava; C Ling
Journal:  Gene Ther       Date:  2011-07-21       Impact factor: 5.250

6.  The anti-cancer potency and mechanism of a novel tumor-activated fused toxin, DLM.

Authors:  Dejun Sun; Miaonan Sun; Wenhe Zhu; Zhiding Wang; Yuefei Li; Jie Ma
Journal:  Toxins (Basel)       Date:  2015-02-04       Impact factor: 4.546

Review 7.  Anticancer Activity of Toxins from Bee and Snake Venom-An Overview on Ovarian Cancer.

Authors:  Marius Alexandru Moga; Oana Gabriela Dimienescu; Cristian Andrei Arvătescu; Petru Ifteni; Liana Pleş
Journal:  Molecules       Date:  2018-03-19       Impact factor: 4.411

8.  Anticancer agent shikonin is an incompetent inducer of cancer drug resistance.

Authors:  Hao Wu; Jiansheng Xie; Qiangrong Pan; Beibei Wang; Danqing Hu; Xun Hu
Journal:  PLoS One       Date:  2013-01-03       Impact factor: 3.240

9.  The membrane effects of melittin on gastric and colorectal cancer.

Authors:  Caroline Soliman; Sarah Eastwood; Vi Khanh Truong; Paul A Ramsland; Aaron Elbourne
Journal:  PLoS One       Date:  2019-10-17       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.